Stephen Hoge Sells 15,000 Shares of Moderna, Inc. (NASDAQ:MRNA) Stock

Moderna, Inc. (NASDAQ:MRNA) President Stephen Hoge sold 15,000 shares of the stock in a transaction dated Monday, April 15th. The shares were sold at an average price of $105.02, for a total transaction of $1,575,300.00. Following the sale, the president now directly owns 1,486,241 shares in the company, valued at $156,085,029.82. The sale was disclosed in a filing with the SEC, which is accessible through this hyperlink.

Stephen Hoge also recently made the following trade(s):

• On Thursday, February 29th, Stephen Hoge sold 2,388 shares of Moderna stock. The shares were sold at an average price of $94.57, for a total transaction of $225,833.16.

Moderna Price Performance

NASDAQ MRNA opened at $102.00 on Friday. Moderna, Inc. has a 12 month low of $62.55 and a 12 month high of $144.43. The stock has a market cap of $39.05 billion, a price-to-earnings ratio of -8.22 and a beta of 1.62. The company’s 50 day moving average is $100.35 and its two-hundred day moving average is $93.65. The company has a current ratio of 3.42, a quick ratio of 3.36 and a debt-to-equity ratio of 0.04.

Moderna (NASDAQ:MRNA) last released its earnings results on Thursday, February 22nd. The company reported $0.55 EPS for the quarter, topping analysts’ consensus estimates of ($0.78) by $1.33. Moderna had a negative net margin of 68.84% and a negative return on equity of 10.23%. The company had revenue of $2.80 billion for the quarter, compared to analysts’ expectations of $2.53 billion. During the same quarter last year, the business earned $3.61 EPS. The firm’s revenue was down 44.9% compared to the same quarter last year. As a group, research analysts anticipate that Moderna, Inc. will post -7.51 earnings per share for the current year.

Analysts Set New Price Targets

A number of brokerages have recently issued reports on MRNA. Royal Bank of Canada reaffirmed an “outperform” rating and set a $125.00 price target on shares of Moderna in a report on Thursday, March 28th. William Blair reaffirmed a “market perform” rating on shares of Moderna in a report on Monday, April 1st. Needham & Company LLC reaffirmed a “hold” rating on shares of Moderna in a report on Thursday, April 11th. Oppenheimer raised shares of Moderna from a “market perform” rating to an “outperform” rating and set a $142.00 price target on the stock in a report on Tuesday, January 2nd. Finally, Canaccord Genuity Group raised their price target on shares of Moderna from $82.00 to $91.00 and gave the company a “hold” rating in a report on Friday, February 23rd. Two research analysts have rated the stock with a sell rating, nine have assigned a hold rating and six have given a buy rating to the company. According to data from MarketBeat.com, the stock has a consensus rating of “Hold” and a consensus target price of $126.49.

Institutional Investors Weigh In On Moderna

A number of institutional investors and hedge funds have recently added to or reduced their stakes in MRNA. RB Capital Management LLC raised its stake in Moderna by 7.5% during the 1st quarter. RB Capital Management LLC now owns 2,267 shares of the company’s stock worth $391,000 after acquiring an additional 158 shares during the period. Synovus Financial Corp raised its position in shares of Moderna by 8.0% during the first quarter. Synovus Financial Corp now owns 4,049 shares of the company’s stock valued at $704,000 after buying an additional 300 shares during the last quarter. Dimensional Fund Advisors LP raised its position in shares of Moderna by 5.1% during the first quarter. Dimensional Fund Advisors LP now owns 987,478 shares of the company’s stock valued at $170,121,000 after buying an additional 47,755 shares during the last quarter. Blair William & Co. IL raised its position in shares of Moderna by 12.4% during the first quarter. Blair William & Co. IL now owns 15,611 shares of the company’s stock valued at $2,689,000 after buying an additional 1,724 shares during the last quarter. Finally, Sei Investments Co. raised its position in shares of Moderna by 41.4% during the first quarter. Sei Investments Co. now owns 58,160 shares of the company’s stock valued at $10,019,000 after buying an additional 17,031 shares during the last quarter. Institutional investors own 75.33% of the company’s stock.

Moderna Company Profile

Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines.